IBDEI01M ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1596,2)
 ;;=^56578
 ;;^UTILITY(U,$J,358.3,1597,0)
 ;;=283.19^^9^88^82
 ;;^UTILITY(U,$J,358.3,1597,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1597,1,4,0)
 ;;=4^283.19
 ;;^UTILITY(U,$J,358.3,1597,1,5,0)
 ;;=5^Hemolytic Anemia,Microang
 ;;^UTILITY(U,$J,358.3,1597,2)
 ;;=^293664
 ;;^UTILITY(U,$J,358.3,1598,0)
 ;;=280.9^^9^88^86
 ;;^UTILITY(U,$J,358.3,1598,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1598,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,1598,1,5,0)
 ;;=5^Iron Defic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,1598,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,1599,0)
 ;;=285.1^^9^88^84
 ;;^UTILITY(U,$J,358.3,1599,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1599,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,1599,1,5,0)
 ;;=5^Iron Defic Anemia d/t Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,1599,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,1600,0)
 ;;=280.0^^9^88^85
 ;;^UTILITY(U,$J,358.3,1600,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1600,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,1600,1,5,0)
 ;;=5^Iron Defic Anemia d/t Chronic Blood Loss
 ;;^UTILITY(U,$J,358.3,1600,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,1601,0)
 ;;=281.9^^9^88^107
 ;;^UTILITY(U,$J,358.3,1601,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1601,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,1601,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,1601,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,1602,0)
 ;;=281.0^^9^88^123
 ;;^UTILITY(U,$J,358.3,1602,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1602,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,1602,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,1602,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,1603,0)
 ;;=282.60^^9^88^111
 ;;^UTILITY(U,$J,358.3,1603,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1603,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,1603,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,1603,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,1604,0)
 ;;=282.62^^9^88^112
 ;;^UTILITY(U,$J,358.3,1604,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1604,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,1604,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,1604,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,1605,0)
 ;;=281.1^^9^88^124
 ;;^UTILITY(U,$J,358.3,1605,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1605,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,1605,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,1605,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,1606,0)
 ;;=286.7^^9^88^54
 ;;^UTILITY(U,$J,358.3,1606,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1606,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,1606,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,1606,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,1607,0)
 ;;=289.9^^9^88^120
 ;;^UTILITY(U,$J,358.3,1607,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1607,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,1607,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,1607,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,1608,0)
 ;;=451.9^^9^88^121
 ;;^UTILITY(U,$J,358.3,1608,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1608,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,1608,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,1608,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,1609,0)
 ;;=446.6^^9^88^122
 ;;^UTILITY(U,$J,358.3,1609,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1609,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,1609,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,1609,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,1610,0)
 ;;=286.4^^9^88^125
 ;;^UTILITY(U,$J,358.3,1610,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1610,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,1610,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,1610,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,1611,0)
 ;;=204.00^^9^88^1
 ;;^UTILITY(U,$J,358.3,1611,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1611,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,1611,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,1611,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,1612,0)
 ;;=204.01^^9^88^3
 ;;^UTILITY(U,$J,358.3,1612,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1612,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,1612,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,1612,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,1613,0)
 ;;=204.10^^9^88^16
 ;;^UTILITY(U,$J,358.3,1613,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1613,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,1613,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,1613,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,1614,0)
 ;;=204.11^^9^88^18
 ;;^UTILITY(U,$J,358.3,1614,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1614,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,1614,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,1614,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,1615,0)
 ;;=201.90^^9^88^83
 ;;^UTILITY(U,$J,358.3,1615,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1615,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,1615,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,1615,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,1616,0)
 ;;=785.6^^9^88^89
 ;;^UTILITY(U,$J,358.3,1616,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1616,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,1616,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,1616,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,1617,0)
 ;;=200.20^^9^88^90
 ;;^UTILITY(U,$J,358.3,1617,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1617,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,1617,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,1617,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,1618,0)
 ;;=202.00^^9^88^92
 ;;^UTILITY(U,$J,358.3,1618,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1618,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,1618,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,1618,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,1619,0)
 ;;=200.10^^9^88^91
 ;;^UTILITY(U,$J,358.3,1619,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1619,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,1619,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,1619,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,1620,0)
 ;;=273.3^^9^88^93
 ;;^UTILITY(U,$J,358.3,1620,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1620,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,1620,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,1620,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,1621,0)
 ;;=203.00^^9^88^103
 ;;^UTILITY(U,$J,358.3,1621,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1621,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,1621,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,1621,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,1622,0)
 ;;=203.01^^9^88^105
 ;;^UTILITY(U,$J,358.3,1622,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1622,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,1622,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,1622,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,1623,0)
 ;;=238.6^^9^88^108
 ;;^UTILITY(U,$J,358.3,1623,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1623,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,1623,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,1623,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,1624,0)
 ;;=205.00^^9^88^4
 ;;^UTILITY(U,$J,358.3,1624,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1624,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,1624,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,1624,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,1625,0)
 ;;=205.01^^9^88^6
 ;;^UTILITY(U,$J,358.3,1625,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1625,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,1625,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,1625,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,1626,0)
 ;;=205.10^^9^88^19
 ;;^UTILITY(U,$J,358.3,1626,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1626,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,1626,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,1626,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,1627,0)
 ;;=205.11^^9^88^21
 ;;^UTILITY(U,$J,358.3,1627,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1627,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,1627,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,1627,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,1628,0)
 ;;=289.0^^9^88^55
 ;;^UTILITY(U,$J,358.3,1628,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1628,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,1628,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,1628,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,1629,0)
 ;;=238.4^^9^88^109
 ;;^UTILITY(U,$J,358.3,1629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1629,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,1629,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,1629,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,1630,0)
 ;;=V58.61^^9^88^126
 ;;^UTILITY(U,$J,358.3,1630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1630,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,1630,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,1630,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,1631,0)
 ;;=282.49^^9^88^117
 ;;^UTILITY(U,$J,358.3,1631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1631,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,1631,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,1631,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,1632,0)
 ;;=289.89^^9^88^15
 ;;^UTILITY(U,$J,358.3,1632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1632,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,1632,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,1632,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,1633,0)
 ;;=238.79^^9^88^88
 ;;^UTILITY(U,$J,358.3,1633,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1633,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,1633,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,1633,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,1634,0)
 ;;=287.30^^9^88^110
 ;;^UTILITY(U,$J,358.3,1634,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1634,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,1634,1,5,0)
 ;;=5^Primary Thrombocytopenia
